- Home
- SPH vs LQDA Comparison
SPH vs LQDA Comparison
Compare SPH & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPH
- LQDA
- Stock Information
- Founded
- SPH 1945
- LQDA 2004
- Country
- SPH United States
- LQDA United States
- Employees
- SPH N/A
- LQDA N/A
- Industry
- SPH Other Specialty Stores
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- SPH Consumer Discretionary
- LQDA Health Care
- Exchange
- SPH Nasdaq
- LQDA Nasdaq
- Market Cap
- SPH 1.2B
- LQDA 1.2B
- IPO Year
- SPH 1996
- LQDA 2018
- Fundamental
- Price
- SPH $18.48
- LQDA $14.09
- Analyst Decision
- SPH Sell
- LQDA Strong Buy
- Analyst Count
- SPH 1
- LQDA 9
- Target Price
- SPH $17.00
- LQDA $27.67
- AVG Volume (30 Days)
- SPH 182.3K
- LQDA 2.1M
- Earning Date
- SPH 08-07-2025
- LQDA 08-06-2025
- Dividend Yield
- SPH 6.98%
- LQDA N/A
- EPS Growth
- SPH N/A
- LQDA N/A
- EPS
- SPH 1.46
- LQDA N/A
- Revenue
- SPH $1,424,243,000.00
- LQDA $14,144,000.00
- Revenue This Year
- SPH $10.99
- LQDA $189.27
- Revenue Next Year
- SPH N/A
- LQDA $402.79
- P/E Ratio
- SPH $12.76
- LQDA N/A
- Revenue Growth
- SPH 4.02
- LQDA N/A
- 52 Week Low
- SPH $15.20
- LQDA $8.26
- 52 Week High
- SPH $22.24
- LQDA $19.41
- Technical
- Relative Strength Index (RSI)
- SPH 48.05
- LQDA 52.19
- Support Level
- SPH $18.05
- LQDA $11.86
- Resistance Level
- SPH $18.71
- LQDA $14.16
- Average True Range (ATR)
- SPH 0.45
- LQDA 0.71
- MACD
- SPH 0.03
- LQDA 0.21
- Stochastic Oscillator
- SPH 39.94
- LQDA 96.97
About SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.